FRBP
Franklin BSP Capital Corp
$8.45
0.00%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
May 8, 2026
SEC
CFO and Treasurer Nina Baryski resigned effective July 27, 2026 to pursue another opportunity, with no disagreement cite
8-K — Impact 4/10
Apr 28, 2026
SEC
Franklin BSP Capital Corp filed a DEFA14A (definitive additional proxy soliciting materials) on April 28, 2026, remindin
DEFA14A — Impact 2/10
Apr 16, 2026
SEC
Franklin BSP Capital Corp. amended its loan agreement to increase the credit facility from $300 million to $400 million,
8-K — Impact 7/10
Latest Reports
NEUTRAL
8-K
4/10
CFO and Treasurer Nina Baryski resigned effective July 27, 2026 to pursue another opportunity, with no disagreement cite
May 8, 2026
NEUTRAL
DEFA14A
2/10
Franklin BSP Capital Corp filed a DEFA14A (definitive additional proxy soliciting materials) on April 28, 2026, remindin
Apr 28, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.6/10.
NEUTRAL
8-K
4/10
CFO and Treasurer Nina Baryski resigned effective July 27, 2026 to pursue another opportunity, with
May 8, 2026
NEUTRAL
DEFA14A
2/10
Franklin BSP Capital Corp filed a DEFA14A (definitive additional proxy soliciting materials) on Apri
Apr 28, 2026
BULLISH
8-K
7/10
Franklin BSP Capital Corp. amended its loan agreement to increase the credit facility from $300 mill
Apr 16, 2026
NEUTRAL
DEFA14A
2/10
This is a definitive proxy statement for Franklin BSP Capital Corp (FRBP) related to an upcoming ann
Apr 16, 2026
NEUTRAL
DEFA14A
3/10
Franklin BSP Capital Corp (FRBP) is holding its annual shareholder meeting on June 5, 2026. Sharehol
Apr 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.